Loading people...
DanDan Dong is a Venture Partner at TCGX and a Board Member at InnoCare Pharma, based in Palo Alto, bringing over fifteen years of experience in global healthcare investment and cross-border biotech company formation. She previously spent a decade as a Managing Director at Vivo Capital, helping lead investment strategies for the prominent global healthcare firm with over $6 billion in assets under management. Dong also served as Chief Business Officer at ArriVent Biopharma and VISEN Pharmaceuticals, and she co-founded RareStone Group to establish the first rare disease ecosystem in Greater China. Throughout her career, she has led investments in prominent biotechnology companies, including Zai Lab, CRISPR Therapeutics, Innovent Biologics, and Gracell. She holds a Ph.D. in Molecular Microbiology from Fudan University, a Bachelor's degree from Sichuan University, and completed pre-doctoral training at New York University.
DanDan Dong serves as a highly respected Managing Director at Vivo Capital, a prominent global healthcare investment firm. In this pivotal role, she is a key driver of the firm's investment strategy, actively involved in identifying, evaluating, and executing strategic investments across the dynamic healthcare landscape. Her responsibilities encompass a broad spectrum, from rigorous due diligence on potential portfolio companies to providing strategic guidance and oversight to existing investments, ensuring their growth and success.
Ms. Dong's investment focus at Vivo Capital is deeply rooted in the healthcare sector, reflecting the firm's core expertise. She specializes in areas such as biotechnology, pharmaceuticals, medical devices, diagnostics, and increasingly, digital health solutions. Her keen eye for innovation and understanding of market trends allow her to pinpoint companies poised for significant impact and growth. She is particularly adept at navigating complex scientific and regulatory environments, making her an invaluable asset to both Vivo Capital and its portfolio companies, whether they are early-stage startups or more mature growth-equity opportunities.
Before her tenure at Vivo Capital, DanDan Dong cultivated a robust career background that provided her with a comprehensive understanding of the life sciences industry. While specific details of her early career are not always publicly detailed, professionals in her position typically bring a rich blend of scientific acumen, operational experience, and financial expertise. This often includes roles in scientific research, clinical development, or strategic consulting within the biotech or pharmaceutical industries, complemented by strong financial analysis skills. Her educational background likely includes advanced degrees in relevant fields, such as biology, chemistry, medicine, or business administration, equipping her with both the scientific foundation and the business acumen essential for successful healthcare investing.
Throughout her career at Vivo Capital, DanDan Dong has been instrumental in numerous successful investments that align with the firm's mission to support companies developing innovative solutions for unmet medical needs. While specific individual deal leadership is often attributed to the firm, her contributions are vital in shaping Vivo Capital's portfolio. Her strategic insights help guide companies through critical development stages, market entry, and expansion, ultimately contributing to improved patient outcomes and significant returns for investors. Her dedication to fostering innovation and her deep industry knowledge solidify her reputation as a leading figure in healthcare venture capital and private equity.
DanDan Dong is a Managing Director at Vivo Capital, a global healthcare investment firm. She plays a crucial role in identifying, evaluating, and executing investments in the healthcare sector.
DanDan Dong invests in various healthcare sectors, including biotechnology, pharmaceuticals, medical devices, diagnostics, and digital health, focusing on companies from early-stage to growth equity.
DanDan Dong works at Vivo Capital, a leading healthcare investment firm.
